Vitrolife Q1 update: Entering 2024 with low growth
Research Update
2024-04-22
08:22
Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024. The combined effect from insourcing (PGT-A), ERA and EmbryoMap switching will likely contribute to a considerable headwind in Q2 (ERA could improve). Our updated view is a base case valuation of SEK 220 (245), a Bull Case of SEK 365(400), and a Bear Case of SEK 95 (100).
JU
Johan Unnerus
Analyst Q&A
Closed
Johan Unnerus answered 3 questions.
Disclosures and disclaimers